P-0146 - To select the therapies in gastric carcinoid tumors

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Neuroendocrine Cancers
Presenter Sei Kurokawa
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors S. Kurokawa
  • Sapporo-Kosei General Hospital, Sapporo/JP



Gastric carcinoid tumors are very rare tumors, the constant opinion is not obtained about the therapy. We estimate future treatment strategy from the clinicopathologic evidence of gastric carcinoid tumors which we experienced in our hospital.


Retrospective analysis of 7 patients from 2006 to 2012 in our hospital.


All of the indications for upper endoscopy were medical examination. Gender, the mean age of patients were 5(Male): 2(Female), 60.7 ± 16.1. Gastric carcinoid type 1 tumors were 3 patients, type 3 were 4 patients. The mean number of lesions, maximum tumoral diameter, and percentage of cells expressing Ki-67 labeling index were 1.57 ± 1.13, 7.5 ± 2.7 mm and 2.1 ± 1.0% respectively. The mean serum gastrin levels of type 1 were 1850 pg/dl. As for the therapy every type category, as for type 1, two distal gastrectomy, total gastrectomy one, type 3 were two distal gastrectomy, ESD1 case, follow-up one. One lymph node metastasis was detected. We survive without all cases recurrence for 42.3 ± 27.8 months for the mean observation period.


The conventional carcinoid tumor came to be named generally by WHO classification of 2010 with Neuroendocrine tumor (NET). The type 1 case chose surgery for a multiple lesion, hypergastrinemia. The case which we locally excised in ESD included type 3 case, but the G2 case that the proliferation potency of cells was high showed lymph node metastases. It seems that the NET needs therapy choice on having evaluated the proliferation potency of cells.